The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than ...

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the ...

Shipping giant CMA CGM and tech startup Mistral AI expect rapid productivity gains from a 100 million euro partnership ...

CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Our sister site, Drug Delivery Business News, reports today that the company won FDA clearance for the 15-day version of its ...

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Experts discuss how to evaluate and communicate the return on investment for continuous glucose monitoring (CGM) coverage to ...

Continuous glucose monitoring with low-glucose alerts shows potential for reducing hypoglycemia risk in insulin-treated ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun ...

Ambrosia, a global leader in real-time health monitoring, has launched India’s first 24×7 real-time glucose and stress ...